| |
original article |
Journal |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
Modern Rheumatology Journal |
2023―Aug―21 |
COVID-19 and post-covid syndrome in patients with rheumatoid arthritis |
E. S. Aronova, B. S. Belov, G. I. Gridneva |
| 2 |
[GO] |
Modern Rheumatology Journal |
2023―Aug―21 |
A clinical case of development of Waterhouse-Friderichsen syndrome after SARS-CoV-2 infection in a patient with rheumatoid arthritis and secondary adrenal AA-amyloidosis |
O. V. Alpidovskaya |
| 3 |
[GO] |
Modern Rheumatology Journal |
2023―Jul―13 |
Retrospective analysis of cases of multisystem inflammatory syndrome associated with COVID-19 infection in children in the Republic of Komi |
N. N. Korableva, O. R. Payusova, E. V. Berestnev, O. N. Tarbeyeva, A. S. Mezentseva, T. V. Bezuglaya |
| 4 |
[GO] |
Modern Rheumatology Journal |
2023―Feb―17 |
Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination |
Sh. F. Erdes, B. S. Belov |
| 5 |
[GO] |
Modern Rheumatology Journal |
2023―Feb―17 |
Clinical case of SARS-CoV-2 infection in a patient with rheumatoid arthritis and secondary AA-amyloidosis of the lungs |
O. V. Vorobeva, L. P. Romanova |
| 6 |
[GO] |
Modern Rheumatology Journal |
2022―Dec―19 |
Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience |
A. I. Zagrebneva, E. N. Simonova, T. V. Mezenova, N. B. Burmistrova, Yu. A. Gavrikova, Yu. A. Gavrikova, et al. (+3) E. O. Morozova, Zh. M. Kodzeva, K. S. Sapogina |
| 7 |
[GO] |
Modern Rheumatology Journal |
2022―Dec―19 |
Development of bilateral episcleritis and rheumatoid arthritis after a new coronavirus infection: a description of a clinical case |
O. N. Matveeva, E. V. Kvasova |
| 8 |
[GO] |
Modern Rheumatology Journal |
2022―Oct―20 |
Pathological changes in organs in rheumatoid arthritis with secondary amyloidosis of the heart and kidneys on the background of COVID-19 |
O. V. Vorobeva, I. P. Romanova |
| 9 |
[GO] |
Modern Rheumatology Journal |
2022―Oct―20 |
Shared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases |
K. S. Rutskaya-Moroshan, S. T. Abisheva, A. M. Lila |
| 10 |
[GO] |
Modern Rheumatology Journal |
2022―Jun―20 |
Current possibilities of pharmacological correction of neuroimmune joint damage in patients with knee osteoarthritis in long COVID conditions |
I. V. Sarvilina, I. S. Dydykina, A. M. Lila |
| 11 |
[GO] |
Modern Rheumatology Journal |
2022―May―08 |
Analysis of the mechanisms of development of neurorheumatological consequences of COVID-19 and the possibility of their pharmacological correction |
I. V. Sarvilina, A. M. Lila, O. A. Gromova, I. Yu. Torshin, O. A. Shavlovskaya, E. A. Taskina |
| 12 |
[GO] |
Modern Rheumatology Journal |
2022―May―08 |
Use of telemedicine consultations in rheumatology during the COVID-19 pandemic |
O. V. Teplyakova, A. A. Morozova |
| 13 |
[GO] |
Modern Rheumatology Journal |
2022―May―08 |
Organ changes after SARS-CoV-2 infection in a patient with systemic sclerosis according to autopsy |
O. V. Vorobeva, L. P. Romanova |
| 14 |
[GO] |
Modern Rheumatology Journal |
2022―Feb―20 |
Important aspects of osteoarthritis therapy during the COVID-19 pandemic |
A. M. Lila, A. G. Chuchalin, I. Yu. Torshin, O. A. Gromova |
| 15 |
[GO] |
Modern Rheumatology Journal |
2022―Feb―20 |
Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data) |
A. N. Kulikov, N. V. Muravyeva, B. S. Belov |
| 16 |
[GO] |
Modern Rheumatology Journal |
2022―Feb―20 |
COVID-19-associated angiitis: literature review and case report |
D. I. Abdulganieva, N. G. Shamsutdinova, A. A. Gaibaryan |
| 17 |
[GO] |
Modern Rheumatology Journal |
2021―Oct―20 |
Polyarthritis associated with COVID-19 (clinical case) |
E. S. Aronova, B. S. Belov |
| 18 |
[GO] |
Modern Rheumatology Journal |
2021―Aug―16 |
Septal panniculitis as manifestation of COVID-19: own data |
O. N. Egorova, R. G. Goloeva, D. I. Abdulganieva |
| 19 |
[GO] |
Modern Rheumatology Journal |
2021―Apr―24 |
The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 |
E. S. Aronova, B. S. Belov |
| 20 |
[GO] |
Modern Rheumatology Journal |
2020―May―31 |
COVID-19: the new challenge for rheumatologists |
B. S. Belov, A. E. Karateev |
| 21 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2024―Feb―26 |
Acute cerebrovascular accidents in patients with new coronavirus infection COVID-19 |
N. A. Shamalov, L. V. Klimov, M. A. Soldatov, T. V. Kiseleva, V. N. Shamalova, N. A. Marskaya, O. V. Lyang |
| 22 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2023―Dec―18 |
Admitting a patient with musculoskeletal pain following COVID-19 disease |
I. D. Romanov, O. A. Shavlovskaya, I. A. Bokova |
| 23 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2023―Dec―18 |
Neurohumoral gate for the entry of coronavirus into the central nervous system through the cribriform plate of the skull |
V. N. Nikolenko, M. V. Oganesyan, N. A. Rizaeva, A. T. Nikitina, M. P. Pavliv, А. V. Polyakova, et al. (+2) E. A. Sozonova, M. N. Khabibov |
| 24 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2023―Jul―05 |
Inflammatory biomarkers and growth factors in patients with chronic cerebrovascular disease after coronavirus infection |
E. B. Kuznetsova, O. N. Voskresenskaya, N. B. Zakharova, N. S. Kuznetsov |
| 25 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2023―Jul―05 |
Mental disorders during the pandemic of a new coronavirus infection: clinical features |
V. A. Vysokova, N. A. Tyuvina, T. N. Maksimova, S. V. Prokhorova |
| 26 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2023―May―01 |
Clinical course and diagnosis of cerebral vein and sinus thrombosis associated with COVID-19 in young and middle-aged patients |
E. G. Klocheva, V. V. Goldobin, F. Z. Olimova |
| 27 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Dec―20 |
Alzheimer's disease and COVID-19 |
N. N. Koberskaya, F. A. Roshchin |
| 28 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Dec―20 |
A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study |
Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova |
| 29 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Dec―20 |
Mental disorders during the pandemic of a new coronavirus infection: causes and predisposing factors |
N. A. Tyuvina, V. O. Vysokova, E. N. Efremova, O. V. Lavrinenko |
| 30 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Oct―25 |
Impact of work and study during pandemic on the mental state of medical professionals |
V. E. Medvedev, O. A. Dogotar, N. Yu. Lyzlova |
| 31 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Aug―24 |
Cognitive impairment in patients with coronavirus infection |
Y. A. Starchina, O. V. Kosivtsova |
| 32 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Aug―24 |
Clinical features of mental disorders during the pandemic of a new coronavirus infection |
N. A. Tyuvina, V. O. Vysokova, E. N. Efremova, O. V. Lavrinenko |
| 33 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Aug―05 |
Review of human interferons and the potential of their use in the complex therapy of a new coronavirus infection COVID-19 |
E. V. Granatov, A. R. Abashev, F. A. Khabirov, A. Ya. Dykhanov, T. I. Khaibullin |
| 34 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Aug―05 |
Autoimmune spinal cord lesions associated with novel coronavirus infection |
A. O. Kozlova, D. D. Eliseeva, T. O. Simaniv, V. V. Bryukhov, E. V. Baidina, M. N. Zakharova |
| 35 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Jun―21 |
Acute and long-term neurological disorders in patients with coronavirus infection |
V. A. Parfenov, A. A. Kulesh |
| 36 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Feb―27 |
COVID-19 associated multiple cranial neuropathies |
M. Yu. Maksimova, Ya. O. Grusha, E. I. Fettser |
| 37 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2022―Feb―27 |
Validation of the Russian version of Stress and Anxiety to Viral Epidemics - 9 items (SAVE-9) among healthcare workers during COVID-19 pandemic |
E. S. Mosolova, S. Chung, D. N. Sosin, S. N. Mosolov |
| 38 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Dec―16 |
Causes and predictors of mental disorders during the COVID-19 pandemic |
N. A. Tyuvina, V. O. Vysokova, T. N. Maksimova, S. V. Prokhorova |
| 39 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Dec―16 |
Multifactorial model of willingness to get vaccinated in medical students during 3rd wave of COVID-19 pandemic |
V. L. Malygin, Ya. V. Malygin, A. S. Iskandirova, E. E. Pahtusova, Yu. A. Merkuryeva, V. V. Ogarev, et al. (+2) A. V. Hudiakov, M. A. Asasian |
| 40 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Dec―16 |
Possibilities of using amantadines in the setting of the novel coronavirus infection in patients with Parkinson's disease |
E. A. Katunina, Yu. N. Bezdolnyi, N. N. Shipilova |
| 41 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Oct―18 |
Management of patients with pain syndromes associated with COVID-19 |
L. T. Akhmedzhanova, T. M. Ostroumova, O. A. Solokha |
| 42 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Oct―18 |
Anticoagulant therapy for stroke prevention in patients with severe COVID-19 |
A. T. Azimov, G. S. Rakhimbaeva, F. Z. Azimov |
| 43 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Oct―18 |
Pathobiochemical pathways of redox imbalance in the neurological long-term effects of COVID-19 and the role of chondroitin sulfate in the redox status restoration |
I. V. Sarvilina, O. A. Gromova, A. V. Naumov |
| 44 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Oct―18 |
Impact of mental disorders on COVID-19 outcomes |
N. N. Petrova, V. E. Pashkovskiy, M. S. Sivashova, A. N. Gvozdetsky, G. A. Prokopovich |
| 45 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Oct―18 |
Obsessive-compulsive disorder during the SARS-CoV-2 pandemic (case report) |
N. A. Tiuvina, T. N. Maksimova, S. V. Prokhorova, V. O. Vysokova |
| 46 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Sep―16 |
Acute inflammatory demyelinating pseudotumor after COVID-19 |
T. I. Yakushina, D. M. Yakushin, I. O. Shtang |
| 47 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Sep―16 |
Current ethical issues of clinical trials of drugs for the pathogenetic therapy of multiple sclerosis in the context of the COVID-19 pandemic |
E. V. Ivashkova, A. M. Petrov, M. V. Votintseva, I. D. Stolyarov |
| 48 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Jun―24 |
COVID-19 and epilepsy: Russian and international experience |
G. V. Odintsova |
| 49 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Jun―24 |
Management tactics in patients with chronic cerebral ischemia during COVID-19 pandemic |
A. A. Kulesh |
| 50 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
Actovegin use in patients with cognitive impairment after coronavirus infection (COVID-19) |
V. A. Kutashov |
| 51 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
COVID-19 vaccination guidelines for patients with multiple sclerosis |
N. V. Khachanova, N. A. Totolyan, Ya. V. Vlasov, S. A. Sivertseva, M. V. Davydovskaya, E. P. Evdoshenko, et al. (+4) A. P. Prodeus, M. N. Zakharova, N. N. Spirin, A. N. Boyko |
| 52 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
Cognitive impairment in COVID-19: associations, pathogenesis and treatment questions |
V. A. Golovacheva, G. R. Tabeeva, I. V. Kuznetsov |
| 53 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
Anxiety and depression in COVID-19: treatment options |
V. E. Medvedev |
| 54 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Apr―25 |
Central pontine myelinolysis in the presence of SARS-CoV-2 infection (clinical observations) |
O. N. Voskresenskaya, A. A. Kovalenko, E. B. Nadbitova, V. V. Grinyuk, A. V. Klimanov, Yu. M. Shor |
| 55 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Feb―18 |
The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’ |
V. V. Kovalchuk |
| 56 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Feb―18 |
Anxiety: phenomenology, epidemiology, and risk factors during the novel coronavirus SARS-CoV-2 (COVID-19) pandemic |
A. G. Merkin, S. S. Akinfieva, A. V. Martyushev-Poklad, O. P. Beloskurskaya, E. N. Dinov, S. L. Ostrovsky, et al. (+5) A. N. Komarov, O. Yu. Zakharova, V. A. Kazhin, I. A. Nikiforov, M. Glover |
| 57 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Feb―18 |
Depression during the COVID-19 pandemic (analysis of clinical cases) |
I. Yu. Dorozhenok |
| 58 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2021―Feb―18 |
Cognitive impairment in COVID-19 survivors |
T. M. Ostroumova, P. A. Chernousov, I. V. Kuznetsov |
| 59 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2020―Dec―13 |
COVID-19 and mental health: challenges and first conclusions |
V. E. Medvedev, O. A. Dogotar |
| 60 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2020―Dec―13 |
Somatization disorders of affective and neurotic registers during the COVID-19 pandemic (analysis of clinical cases) |
I. Yu. Dorozhenok |
| 61 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2020―Aug―05 |
Nervous system damage in COVID-19 with an emphasis on the management of patients with multiple sclerosis |
A. N. Boyko, S. A. Sivertseva, N. N. Spirin |
| 62 |
[GO] |
Neurology neuropsychiatry Psychosomatics |
2020―Jun―26 |
The first experience with Angiovit in the combination treatment of acute COVID-19 infection |
A. N. Boyko, N. A. Shamalov, O. V. Boyko, E. E. Arinina, O. V. Lyang, E. A. Dubchenko, et al. (+2) A. V. Ivanov, A. A. Kubatiev |
| 63 |
[GO] |
Rheumatology Science and Practice |
2020―Jun―24 |
DO NSAIDS CAUSE SPECIFIC COMPLICATIONS IN COVID-19 CORONAVIRUS INFECTION? |
A. E. Karateev, E. L. Nasonov, A. M. Lila |
| 64 |
[GO] |
Rheumatology Science and Practice |
2020―Jun―24 |
IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6 |
E. L. Nasonov |
| 65 |
[GO] |
Rheumatology Science and Practice |
2020―Apr―27 |
CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS |
E. L. Nasonov |
